Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2018 13:41 ET | Source: Targazyme, Inc.

Targazyme Presents TZ-102 Cancer Immunotherapy Preclinical Results at the World Orphan Drug Congress

CARLSBAD, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Targazyme, Inc. a late clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy...
March 06, 2017 18:35 ET | Source: Targazyme, Inc.

Targazyme, Inc. Receives FDA Clearance For a Phase 2 Study of Pediatric Cancer Patients Undergoing Stem Cell Transplantation For Treatment of Hematologic Malignancies

SAN DIEGO,CA--(Marketwired - March 06, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme products to improve clinical efficacy, safety and cost of care...
January 18, 2017 16:16 ET | Source: Targazyme, Inc.

Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes

CARLSBAD, CA--(Marketwired - January 18, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy, safety and...
October 24, 2016 19:00 ET | Source: Targazyme, Inc.

Targazyme, Inc. Receives FDA Clearance for a Phase II Haplo-Identical Transplant Study of Patients Undergoing Bone Marrow Transplantation for Treatment of Hematologic Malignancies

SAN DIEGO, CA--(Marketwired - October 24, 2016) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy and cost of...
July 20, 2016 18:45 ET | Source: Targazyme, Inc.

Targazyme Enrolls First Patient in Phase 1/2 Study of TZ101 Fucosylated Regulatory T Cells to Treat and Prevent Graft vs Host Disease in the Transplant Setting

SAN DIEGO, CA--(Marketwired - July 20, 2016) - Targazyme, Inc. a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy outcomes for...
November 12, 2015 15:39 ET | Source: Targazyme, Inc.

Targazyme and University of Minnesota Medical Center Initiate a Collaboration to Improve Regulatory T Cell Immunotherapy Outcomes for the Prevention and Treatment of Graft-Versus-Host-Disease

SAN DIEGO, CA--(Marketwired - November 12, 2015) - Targazyme, Inc. a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy outcomes...
July 27, 2015 15:48 ET | Source: Targazyme, Inc.

Targazyme Inc. Receives National Cancer Institute SBIR Award for Phase 2 Clinical Study of TZ101-Treated Regulatory T Cell Therapy for Prevention/Treatment of GVHD

SAN DIEGO, CA--(Marketwired - July 27, 2015) - Targazyme, Inc., a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for stem cell...
April 23, 2015 12:02 ET | Source: Targazyme, Inc.

Targazyme, Inc., Announces FDA Concurrence on Targazyme's Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

SAN DIEGO, CA--(Marketwired - April 23, 2015) - Targazyme, Inc., announced today that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company's Special...
March 17, 2015 15:24 ET | Source: Targazyme, Inc.

Targazyme, Inc. and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

SAN DIEGO, CA--(Marketwired - March 17, 2015) - Targazyme, Inc., a clinical stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for a variety of...
February 10, 2015 19:47 ET | Source: Targazyme, Inc.

Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

SAN DIEGO, CA--(Marketwired - February 10, 2015) - Targazyme Inc., a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for stem cell...